Ibutamoren

From Wikipedia, the free encyclopedia
  (Redirected from MK-677)
Jump to: navigation, search
Ibutamoren
Ibutamoren skeletal.svg
Systematic (IUPAC) name
(R)-1'-(2-methylalanyl-O-benzyl-D-seryl)-1-(methylsulfonyl)-1,2-dihydrospiro[indole-3,4'-piperidine]
Clinical data
Legal status
  • US: unscheduled
Identifiers
CAS number 159634-47-6 YesY
159752-10-0 (mesylate salt)
ATC code None
PubChem CID 9939050
ChemSpider 154975
UNII GJ0EGN38UL
Synonyms 2-Amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide
Chemical data
Formula C27H36N4O5S 
Mol. mass 528.662 g/mol
 YesY (what is this?)  (verify)

Ibutamoren (MK-677, L-163,191) is a drug which acts as a potent, orally active growth hormone secretagogue,[1][2] mimicking the GH stimulating action of the endogenous hormone ghrelin.[3][4] It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels.[5] It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults,[6][7][8] and human studies have shown it to increase both muscle mass and bone mineral density,[9][10] making it a promising therapy for the treatment of frailty in the elderly.[11][12] It also alters metabolism of body fat and so may have application in the treatment of obesity.[13][14]

See also[edit]

References[edit]

  1. ^ Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences USA. 1995 Jul 18;92(15):7001-5. PMID 7624358
  2. ^ Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Molecular Endocrinology. 1996 Jan;10(1):57–61. PMID 8838145
  3. ^ Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. Journal of Clinical Endocrinology and Metabolism. 2001 Apr;86(4):1738–45. PMID 11297611
  4. ^ Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW. Overlapping Binding Site for the Endogenous Agonist, Small Molecule Agonists and Ago-allosteric Modulators on the Ghrelin Receptor. Molecular Pharmacology. 2008 Oct 15. PMID 18923064
  5. ^ Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism. 1996 Aug;81(8):2776-82. PMID 8768828
  6. ^ Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996 Dec;81(12):4249-57. PMID 8954023
  7. ^ Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Progress in Hormone Research. 1997;52:215-46. PMID 9238854
  8. ^ Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. Journal of Clinical Endocrinology and Metabolism. 1997 Oct;82(10):3455-63. PMID 9329386
  9. ^ Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. Journal of Bone and Mineral Research. 1999 Jul;14(7):1182-8. PMID 10404019
  10. ^ Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism. 2001 Mar;86(3):1116–25. PMID 11238495
  11. ^ Smith RG, Sun Y, Jiang H, Albarran-Zeckler R, Timchenko N. Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging. Annals of the New York Academy of Sciences. 2007 Nov;1119:147-64. PMID 18056963
  12. ^ An Anti-frailty Pill For Seniors? New Drug Increases Muscle Mass In Arms And Legs Of Older Adults. ScienceDaily November 5th, 2008
  13. ^ Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1998 Feb;83(2):362-9. PMID 9467542
  14. ^ Svensson J, Jansson JO, Ottosson M, Johannsson G, Taskinen MR, Wiklund O, Bengtsson BA. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). Journal of Clinical Endocrinology and Metabolism. 1999 Jun;84(6):2028–33. PMID 10372705